Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Food or edible as carrier for pharmaceutical
Reexamination Certificate
2002-02-11
2003-04-01
Lilling, Herbert J. (Department: 1651)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Food or edible as carrier for pharmaceutical
C424S535000, C424S780000, C426S007000, C426S034000, C435S042000, C435S252100, C435S252400, C435S253400, C435S854000, C435S885000
Reexamination Certificate
active
06541027
ABSTRACT:
The invention relates to novel strains of lactic ferments and to their use for the production of foods endowed with anxiolitic properties.
Stress, which is a defensive reaction of the body against external attacks, causes in particular at the level of the nervous system, biological disruptions which can develop into various pathological conditions. The latter can manifest themselves directly at the psychological level, in particular in the form of anxiety, and/or can take the form of somatic manifestations, such as high blood pressure, gastric ulcerations and the like. They frequently progress to chronic states.
To treat the consequences of stress, whether involving anxiety or somatic manifestations, anxiolytic, and in particular benzodiazepines, are frequently used. However, these medicaments, which can rapidly cause a phenomenon of addiction, may not be suitable for a long-term treatment. Moreover, their anxiolytic action is accompanied in particular by sedative properties which can cause unwanted side effects.
Some research studies have demonstrated the existence, in milk or in products derived therefrom, of substances endowed with pharmacological properties toward pathological conditions linked to stress. In particular, PCT application WO 98/05343, in the names of CALPIS CO. AND GROUPE DANONE, describes an agent possessing antistress properties manifested by an antihypertensive effect. This agent is obtained by fermenting milk with a lactic acid bacterium of the genus Lactobacillus, in particular Lactobacillus helveticus. It is resistant to sterilization and can be used to prepare foods participating in the prevention and/or treatment of the peripheral (somatic) effects of stress, and which can be consumed in the context of the usual diet, regularly and over long periods. No central, in particular anxiolytic, effect resulting from the administration of this agent is demonstrated in PCT application WO 98/05343.
Application EP 95402697 in the name of: SOCIETE COOPERATIVE LAITIERE AGRICOLE D'ARTOIS ET DES FLANDRES, LA PROSPERITE FERMIERE, describes a decapeptide resulting from the tryptic hydrolysis of casein csl. The parental administration of this decapeptide, or of the tryptic hydrolysate comprising it induces an anxiolytic and anticonvulsant effect of the same type as that by the benzodiazepines. On the other hand, this document provides no information relating to the activity of this hydrolysate when administered orally, and the possibility of incorporating it into foods in order to confer antistress properties on them.
The inventors have now demonstrated, in dairy products fermented by certain strains of lactic acid bacteria, the existence of one or more active ingredients capable of inducing, when they are administered orally, an anxiolytic-type antistress effect, without possessing the sedative properties of the benzodiazepines.
The subject of the present invention is also the use of at least one of the newly isolated and characterized strains of lactic acid bacteria mentioned above, for the production of a nonsedative anxiolytic.
The subject of the present invention is a strain of lactic acid bacterium chosen from the group consisting of:
the
Streptococcus thermophilus
S242 strain deposited on Feb. 24, 1999 in accordance with the Budapest Treaty at the CNCM (Collection Nationale de Cultures de Micro-organismes), 28 rue du Docteur Roux, 75724 Paris, under the number I-2130;
the
Streptococcus thermophilus
S003 strain deposited on 24 February 1999 in accordance with the Budapest Treaty at the CNCM (Collection Nationale de Cultures de Micro-organismes), 28 rue du Docteur Roux, 75724 Paris, under the number I-2129;
the
Lactobacillus gasseri
L012 strain deposited on Feb. 24, 1999 in, accordance with the Budapest Treaty at the. :-CNCM (Collection Nationale de Cultures de Micro-organismes), 28 rue du Docteur Roux, 75724 Paris, under the number I-2131;
the
Lactobacillus acidophilus
L030 strain deposited on Feb. 24, 1999 in accordance with the Budapest Treaty at the CNCM (Collection Nationale de Cultures de Micro-organismes), 28 rue du Docteur Roux, 75724 Paris, under the number I-2132.
The subject of the present invention is also the newly isolated and characterized strains of lactic acid bacteria mentioned above, which can be used for the production of a nonsedative anxiolytic.
The characteristics of the strains of lactic acid bacteria in accordance with the invention are summarized in tables I and II below.
TABLE I
Strain
S003
S242
L012
L030
CNCM No.
I-2129
I-2130
I-2131
I-2132
Morphology
Fairly large
Small cocci
Small fine
Medium-
cocci
in pairs or
bacilli,
sized
predominantly
in the form
faintly
bacilli,
in the form
of short
colored,
isolated
of long
chains
often coco-
or in the
chains and a
bacillary
form of
few in the
short
form of
chains
medium and
short chains
Gram +
Gram +
Gram +
Gram +
Metabolism
Oxidase:-
Oxidase:-
Oxidase:-
Oxidase:-
Catalase:-
Catalase:-
Catalase:-
Catalase:-
Facultative
Facultative
Nitrate
Nitrate
aero-
aero-
reductase:-
reductase:-
anaerobe
anaerobe
Nitrite
Nitrite
reductase:-
reductase:-
Aero-
Aero-
anaerobe
anaerobe
Growth T °
37-44° C.
37-44° C.
37-44° C.
37-44° C.
TABLE II
Strain
S003
S242
L012
L030
CNCM No.
I-2129
I-2130
I-2131
I-2132
Galactose
−
−
+
+
D-Glucose
+
+
+
+
D-Fucose
−
−
+
+
D-Mannose
−
−
+
+
N-Acetyl-Glucosamine
−
−
+
+
Amygdalin
−
−
+
+
Arbutin
−
−
+/−
+
Esculin
−
−
+
+
Salicin
−
−
+
+
Cellobiose
−
−
+
+
Matose
−
−
+
+
Sucrose
+
+
+
+
Threalose
−
−
+
+
&bgr;-Gentobiose
−
−
+
+
D-Tagatose
−
−
+
−
D-Turanose
−
−
−
+
Lactose
+
+
+
+
D-Raffinose
−
−
−
+
Melibiose
−
−
−
+
&agr;-Methyl-D-Glucoside
−
−
−
+
The present invention relates in particular to the use, for the production of a nonsedative anxiolytic, of at least one
Streptococcus thermophilus
strain chosen from the S242 strain and the S003 strain, combined with the
S. thermophilus
S147 strain deposited at the CNCM on Dec. 30, 1994 under the number I-1520.
The present invention also relates to lactic ferments comprising at least one strain in accordance with the invention, advantageously combined with another strain of lactic acid bacterium.
According to a preferred embodiment of a lactic ferment in accordance with the invention, it comprises at least the
S. thermophilus
S242 strain and/or the
S. thermophilus
S003 strain, advantageously combined with the
S. thermophilus
S147 strain.
The subject of the present invention is also a non-sedative anxiolytic comprising at least one strain of lactic acid bacterium in accordance with the invention as defined above, or capable of being obtained from a culture of said strain.
For the production of a nonsedative anxiolytic in accordance with the invention, at least one strain of lactic acid bacterium in accordance with the invention is cultured; in particular a lactic ferment comprising at least the
S. thermophilus
S424 strain and/or the
S. thermophilus
S003 strain advantageously combined with the
S. thermophilus
S147 strain, and optionally with the
L. gasseri
L012 strain and/or the
L. acidophilus
L030 strain, is cultured in an appropriate medium, that is to say a medium comprising at least one substrate allowing the growth of said bacteria. Said culture medium is preferably milk or a milk-based medium. It may be chosen in particular from the milks of the various species of mammals, optionally semiskimmed or skimmed, the products resulting from the dilution or the concentration of these milks, such as for example ultrafiltration of diafiltration retentates, milk-based media, such as for example bases for milk-based foods, bases for yogurt and the
Antoine Jean-Michel
Cayuela Chantal
Degivry Marie-Christine
Latge Christian
Postaire Eric
Alston & Bird LLP
Compagnie Gervais Danone
Lilling Herbert J.
LandOfFree
Lactic acid bacteria with anxiolytic properties and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactic acid bacteria with anxiolytic properties and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactic acid bacteria with anxiolytic properties and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3056581